129 / 140
Principios generales de tratamiento particularizado de los sarcomas de partes blandas según histología
>
129
121. Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case
series analysis from the Italian Rare Cancer Network. Ann Oncol 2012;23:501-8.
122. Wilson R, Glaros S, Brown RK, et al. Complete radiographic response of primary pulmonary angiosarcomas
fol- lowing gemcitabine and taxotere. Lung Cancer 2008;61:131-6.
123. Shkoukani MA, Carron MA, Tulunay O, et al. Angiosarcoma of the scalp with complete response to a biweekly
gemcitabine and docetaxel (GEMDOC) chemotherapy regimen. Ear Nose Throat J 2011;90:E26-9.
124. Arnaout A, Wedman DM, El-Sayed S, et al. Neoadjuvant gemcitabine-taxane chemotherapy for radiation- in-
duced angiosarcoma of the breast: a case report. Breast J 2012;18:276-8.
125. Lu HJ, Chen PC, Yen CC, et al. Refractory cutaneous angiosarcoma successfully treated with sunitinib. Br J
Dermatol 2013. DOI:10.1111/bjd.12258.
126. Yoo C, Kim JE, Yoon SK, et al. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib.
Sarcoma 2009;2009:360875. DOI: 10.1155/2009/360875. Epub 2009 May 20.
127. Kollár A, Jones RL, Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and
Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 2016;14:1-5.
128. Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevaci-
zumab in patients with advanced angiosarcoma: a randomized phase II trial. J Clin Oncol 2015;33:2797-802
Sarcoma alveolar
129. Reichardt P, Lindner T, Pink D, et al. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J
Cancer 2003;39:1511-6.
130. Pink D, Bertz-Lepel J, Busemann C, et al. Efficacy of Trabectedin in Patients with Advanced or Metastatic
Alveolar Soft-Part Sarcoma. Onkologie 2012;35(5):249-52.
131. Andrew J, Wagner MD, Goldberg MG, et al. Tivantinib (ARQ 197), a Selective Inhibitor of MET, in Patients
With Microphthalmia Transcription Factor-Associated Tumors. Cancer 2012;118:5894-902.
132. Van Ruth S, van Coevorden F, Peterse JL, et al. Alveolar soft part sarcoma. a report of 15 cases. Eur J Cancer
2002;38:1324-8.
133. Kuriyama K, Todo S, Hibi S, et al. Alveolar soft part sarcoma with lung metastases. Response to interferon
alpha-2a? Med Pediatr Oncol 2001;37:482-3.
134. Bisogno G, Rosolen A, Carli M. Interferon alpha for alveolar soft part sarcoma. Pediatr Blood Cancer
2005;44:687-8.
135. Roozendal KJ, de Valk B, ten Velden JJA, et al. Alveolar soft-part sarcoma responding to interferon alpha-2b.
Brit J Cancer 2003;89:243-5.
136. Stacchiotti S, Tamborini E, Marrari A, et al. Response to Sunitinib Malate in Advanced Alveolar Soft Part
Sarcoma. Clin Cancer Res 2009;15(3)1.
137. Azizi AA, Haberler C, Czech T, et al. Vascular-endothelial-growth-factor (VEGF) expression and possi-
ble response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol
2006;7:521-3.
138. Mir O, Boudou-Rouquette P, Larousserie F, et al. Durable clinical activity of single-agent bevacizumab in a
nonagenarian patient with metastatic alveolar soft part sarcoma. Anticancer Drugs 2012;23(7):745-8.
139. Gardner K, Judson I, Leahy M, et al. Activity of cediranib, a highly potent and selective VEGF signaling in-
hibitor, in alveolar soft part sarcoma. J Clin Oncol 2009;27:541s (suppl: Abstr 10523).
Sarcoma de células claras
140. Finley JW, Hanypsiak B, Mcgrath B, et al. Clear Cell Sarcoma: The Roswell Park Experience. J Surg Oncol
2001;77:16-20.
141. Kawai A, Hosono A, Nakayama R, et al. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients.
Cancer 2007;109:109-16.
142. Jones RL, Constantinidou A, Thway K, et al. Chemotherapy in clear cell sarcoma. Med Oncol 2011;28:859-63.
143. Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best sup-
portive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.
Lancet Oncol 2015;16:406-16